country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189033

Copy Link Print Information

NE58027

NE58027 is a farnesyl pyrophosphate synthase (FPPS) inhibitor with IC₅₀ values of 591.6 nM and 13.7 nM against the human target. NE58027 is an analog of Risedronic acid (HY-B0148). NE58027 causes downstream accumulation of isopentenyl pyrophosphate and the cytotoxic ATP analog ApppI in human breast cancer cells. NE58027 can be used in breast cancer-related research.

For research use only. We do not sell to patients.

CAS No.: 116162-16-4
Formula: C₇H₁₇NO₇P₂
Molecular Weight:289.16

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (285 KB)

NE58027 Chemical Structure

CAS No.: 116162-16-4

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Anti-cancerOthers

Anti-cancer

NE58027 (30 µM) inhibits FPPS in MCF-7 cells and induces IPP/ApppI accumulation^[2].

Others

NE58027 inhibits human FPPS in a cell-free biochemical assay, with an initial IC₅₀ of 591.6 nM and a final IC₅₀ of 13.7 nM after 10 min of preincubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

CAS No. 116162-16-4
Molecular Weight 289.16
Formula C₇H₁₇NO₇P₂
SMILES

O=P(O)(C(CC1NCCCC1)(P(O)(O)=O)O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Fernández D, et al. Human farnesyl pyrophosphate synthase inhibition by nitrogen bisphosphonates: a 3D-QSAR study. Journal of Computer-Aided Molecular Design, 2013, 27: 739-754.

[2]. Räikkönen J, et al. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells. Biochemical and biophysical research communications. 2011 Apr 22;407(4):663-7. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote